The Incidence Rate of Hand-Foot Syndrome Post Capecitabine Administration in the Case of Adenocarcinoma Colorectal from January-August 2019 at Dr. Moewardi General Hospital Surakarta

Aims: To inform the increase of Hand-Foot Syndrome (HFS) incidence in patients with Colorectal Adenocarcinoma after giving capecitabine in Dr. Moewardi General Hospital Surakarta during the period January 2019 to August 2019 based on variables, including the degree and dose of capecitabine

Study Design: This research is a retrospective descriptive research type.

Place and Duration of Study: This research was conducted at the Dr. Moewardi General Hospital Surakarta from January 2019 to August 2019, for approximately eight months.

Methodology: The sample in this study was all patients who underwent routine control by the Digestive Surgery Department in Dr. Moewardi General Hospital Surakarta with a diagnosis of Adenocarcinoma Colorectal and receiving capecitabine therapy. All medical records of patients with Colorectal Adenocarcinoma treated with capecitabine were collected and analyzed. The variables collected were HFS grade and capecitabine dosage.

Results: There were 20 patients diagnosed with Colorectal Adenocarcinoma who underwent therapy with capecitabine. The incidence of Hand-Foot Syndrome in patients who were given a dose of capecitabine showed that at a dose of 1250 mg/m2 (12 people), there were no HFS symptoms. At a dose of 2000 mg/m2 (5 people), HFS symptoms were obtained from degrees 1-2. Then, at a dose of 2500 mg/m2 (3 people), the symptoms of HFS were at grade 3. Although HFS is not a life-threatening complication, it significantly reduces the patient's quality of life.

Conclusions: The incidence of Hand-Foot Syndrome is influenced by the dose of capecitabine administration. The higher the dose given, the higher the degree of HFS occurrence.